LDN for Crohn's Disease—Penn State College of Medicine, Hershey, PA
Dr. Jill P. Smith's most recent research on the effects of LDN is a
double-blind, placebo-controlled Phase II study of youngsters from ages 6 to 17
with active Crohn's disease. It was launched at Penn State in July 2008 and
completed in 2011. Patients were treated with either naltrexone or placebo for
the first 8 weeks, then all subjects received the active low dose naltrexone
drug for the last 8 weeks. This trial has been accepted for publication in the
Clinical Journal of Gastroenterology. (Please see the trial website, here:
http://www.clinicaltrials.gov/ct2/show/NCT00715117?term=crohns+smith&rank=2 
Now to await the report
